Tuesday 10th March - Main Conference Day One - PT (Pacific Time, GMT-08:00)
Presentations on novel engineering strategies, such as targeted gene integration and transposase-based systems, to enable expression of complex biologics. Speakers will demonstrate how these approaches accelerated development timelines and improved productivity without compromising product quality.
Presentations on applying AI and predictive models to optimize cell culture processes, improving productivity and maintaining product quality.
A high-level overview of CGT market trends, manufacturing challenges, and regulatory updates, providing context for the technical discussions that follow.
Case studies showcasing the use of automation and machine learning to rapidly screen and select high-producing cell clones. Presenters will highlight how AI-driven models shortened development cycles and improved clone selection accuracy.
Exploration of next-generation gene editing platforms such as Cas-CLOVER and advanced CRISPR systems for enhancing industrial cell line development, with an emphasis on integration efficiency and freedom-to-operate.
Presentations on media and feeding strategies to support intensified processes, improve cell densities, and enhance titers without compromising product quality.
Presentations showcasing how automation and closed-system processing are improving consistency, efficiency, and chain-of-identity tracking in autologous cell therapy production.
Presentations on applying machine learning and multi-omics data integration to predict cellular behavior, optimize media, and enhance clone selection for improved titer and quality.
Industry experts will share best practices for maintaining genetic stability, managing cell banks, and ensuring consistent product quality from early development through commercial manufacturing.
A comparative discussion on the unique manufacturing, supply chain, and scalability challenges of autologous (patient-specific) and allogeneic (universal donor) cell therapies.